A phase III, randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a CDK4/6 inhibitor, in patients with estrogen receptor-positive, HER2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy
A phase III, randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a CDK4/6 inhibitor, in patients with estrogen receptor-positive, HER2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy
Patologie
Stato
Aperto - reclutamento in corso
Codice studio
CO44657 (pionERA)
Codice EudraCT
2022-502980-39-00
Sponsor/Promotore
F. Hoffmann-La Roche Ltd
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator